LIDOCAINE HYDROCHLORIDE W Drug Patent Profile

When do Lidocaine Hydrochloride W patents expire, and when can generic versions of Lidocaine Hydrochloride W launch?

Lidocaine Hydrochloride W is a drug marketed by Abbott, Bel Mar, Dell Labs, Intl Medication, and Watson Labs. and is included in eight NDAs.

The generic ingredient in LIDOCAINE HYDROCHLORIDE W is epinephrine; lidocaine hydrochloride. There are twenty-one drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the epinephrine; lidocaine hydrochloride profile page.

Summary for LIDOCAINE HYDROCHLORIDE W

US Patents:	0
Applicants:	5
NDAs:	8
DailyMed Link:	LIDOCAINE HYDROCHLORIDE W at DailyMed

US Patents and Regulatory Information for LIDOCAINE HYDROCHLORIDE W

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Watson Labs	LIDOCAINE HYDROCHLORIDE W/ EPINEPHRINE	epinephrine; lidocaine hydrochloride	INJECTABLE;INJECTION	080377-003	Approved Prior to Jan 1, 1982		DISCN	No	No
Bel Mar	LIDOCAINE HYDROCHLORIDE W/ EPINEPHRINE	epinephrine; lidocaine hydrochloride	INJECTABLE;INJECTION	080820-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Abbott	LIDOCAINE HYDROCHLORIDE W/ EPINEPHRINE	epinephrine; lidocaine hydrochloride	INJECTABLE;INJECTION	083154-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Dell Labs	LIDOCAINE HYDROCHLORIDE W/ EPINEPHRINE	epinephrine; lidocaine hydrochloride	INJECTABLE;INJECTION	083389-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Watson Labs	LIDOCAINE HYDROCHLORIDE W/ EPINEPHRINE	epinephrine; lidocaine hydrochloride	INJECTABLE;INJECTION	085463-001	Approved Prior to Jan 1, 1982		DISCN	No	No